1 ic myositis but can be a feature of systemic
hypereosinophilic conditions such as eosinophilia-myalgi
2 tential in the treatment of asthma and other
hypereosinophilic diseases.
3 Induction of EAM in
hypereosinophilic IL-5Tg mice resulted in eosinophilic m
4 deletion of Eos from NJ1638 IL-5 transgenic
hypereosinophilic mice (previously shown to display prof
5 Lesion severity was increased in transgenic
hypereosinophilic mice.
6 recent diagnostic developments, diagnosis of
hypereosinophilic MPN is only made in 10-20% of patients
7 Patients with
hypereosinophilic MPNs associated with PDGFRA and PDGFRB
8 tablished a semi-molecular classification of
hypereosinophilic MPNs.
9 ster analysis identified three clusters: (i)
hypereosinophilic (
n = 71, 16.5%), (ii) high immunologic
10 Finally, a retrospective clinical study of
hypereosinophilic patients revealed a direct correlation
11 reported to be effective in the treatment of
hypereosinophilic syndrome (HES) and a rare eosinophilia
12 ity in identifying a subset of patients with
hypereosinophilic syndrome (HES) and an underlying myelo
13 Idiopathic
hypereosinophilic syndrome (HES) and chronic eosinophili
14 None (0%) of 57 patients with the
hypereosinophilic syndrome (HES) but 10 (56%) of 19 pati
15 Idiopathic
hypereosinophilic syndrome (HES) is a myeloproliferative
16 Idiopathic
hypereosinophilic syndrome (HES) is a myeloproliferative
17 In 2012, idiopathic
hypereosinophilic syndrome (HES) is still the prevalent
18 Four patients with
hypereosinophilic syndrome (HES) refractory to or intole
19 Hypereosinophilic syndrome (HES) represents a group of i
20 cytic leukemia (CMML), 101 with MDS, 11 with
hypereosinophilic syndrome (HES), 8 with systemic mastoc
21 ene has been identified as a cause of clonal
hypereosinophilic syndrome (HES), called F/P-positive ch
22 (SM) and chronic eosinophilic leukemia (CEL)/
hypereosinophilic syndrome (HES).
23 nule proteins were lower than in nonfamilial
hypereosinophilic syndrome (HES).
24 s of imatinib response in clinically-defined
hypereosinophilic syndrome (HES).
25 therapeutic target for imatinib mesylate in
hypereosinophilic syndrome (HES).
26 ondary causes of eosinophilia, an idiopathic
hypereosinophilic syndrome (I-HES) was diagnosed.
27 esulting in the development of an idiopathic
hypereosinophilic syndrome (IHES) with eosinophilic derm
28 eosinophilic leukemia and in the idiopathic
hypereosinophilic syndrome also have been further define
29 ively controls eosinophilia in patients with
hypereosinophilic syndrome and normal interleukin-5 conc
30 eceptor alpha (PDGFRalpha) as a cause of the
hypereosinophilic syndrome and of chronic eosinophilic l
31 DGFRalpha fusion kinase in about half of the
hypereosinophilic syndrome cases.
32 For example, patients with the
hypereosinophilic syndrome have received mepolizumab, an
33 A
hypereosinophilic syndrome in patients after liver trans
34 Idiopathic
hypereosinophilic syndrome involves a prolonged state of
35 The
hypereosinophilic syndrome is a group of diseases charac
36 Hypereosinophilic syndrome is a heterogeneous group of r
37 The idiopathic
hypereosinophilic syndrome is a rare hematologic disorde
38 very of the FIP1L1-PDGFRA fusion gene in the
hypereosinophilic syndrome is an example of the power of
39 or patients in whom no underlying disease or
hypereosinophilic syndrome is found, the term hypereosin
40 The
hypereosinophilic syndrome may result from a novel fusio
41 Patients with
hypereosinophilic syndrome show persistent eosinophilia
42 Ulcerated lesions from patients with the
hypereosinophilic syndrome showed ECP and EDN deposition
43 We treated 11 patients with the
hypereosinophilic syndrome with imatinib and identified
44 ssful empiric treatment of patients with the
hypereosinophilic syndrome with the selective tyrosine k
45 pression was decided in four patients due to
hypereosinophilic syndrome, parvovirus infection, aspira
46 ch cause chronic myelomonocytic leukemia and
hypereosinophilic syndrome, respectively.
47 Although studied in idiopathic
hypereosinophilic syndrome, the therapeutic niche of ant
48 humans and dysregulated in individuals with
hypereosinophilic syndrome, this long non-coding RNA may
49 nologic conditions, and various forms of the
hypereosinophilic syndrome.
50 atory diseases including allergic asthma and
hypereosinophilic syndrome.
51 ive as a corticosteroid-sparing agent in the
hypereosinophilic syndrome.
52 with no increase in clinical activity of the
hypereosinophilic syndrome.
53 antibody, mepolizumab, in patients with the
hypereosinophilic syndrome.
54 ents negative for FIP1L1-PDGFRA who have the
hypereosinophilic syndrome.
55 d thrombotic diathesis characteristic of the
hypereosinophilic syndrome.
56 eosinophilia-myalgia syndrome and idiopathic
hypereosinophilic syndrome.
57 Although most patients with
hypereosinophilic syndromes (HES) present with clinical
58 In 1968, the term
hypereosinophilic syndromes (HES) was coined to refer to
59 Hypereosinophilic syndromes (HESs) are a diverse group o
60 Hypereosinophilic syndromes (HESs) are a group of rare d
61 Hypereosinophilic syndromes (HESs) are a heterogeneous g
62 Hypereosinophilic syndromes (HESs) are chronic disorders
63 Hypereosinophilic syndromes (HESs) are disorders charact
64 The contemporary definition of the
hypereosinophilic syndromes encompasses a range of eosin
65 tail the diagnosis and management of various
hypereosinophilic syndromes including the clonal eosinop
66 As our understanding of the various
hypereosinophilic syndromes increases, and we are able t
67 These may also prove useful for other
hypereosinophilic syndromes without PDGFRA or PDGFRB rea
68 asthma, allergic and parasitic diseases, and
hypereosinophilic syndromes, in addition to more recentl
69 n eosinophilic leukemia and the 'idiopathic'
hypereosinophilic syndromes.
70 riation (mean decrease, -40.9 mL/y), and (3)
hypereosinophilic with low variation (mean decrease in l